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ABSTRACT 
Hepatitis C infection is a growing public health concern, exacerbated by the opioid 
epidemic that continues to make headlines in Southwestern Pennsylvania and across the United 
States.  With the primary means of transmission being blood borne from percutaneous exposure, 
the hepatitis C virus (HCV) is most commonly spread among injection drug users through unsafe 
injection practices.  Although measures are being taken to aid individuals with substance use 
disorder (SUD) access efficacious treatments for cessation, such as Medication Assisted 
Treatment (MAT), few SUD treatment programs incorporate a hepatitis C education curriculum 
emphasizing how to prevent infection and transmission of HCV. A group of individuals that is 
overlooked when considering the long-term burden of HCV infection is pregnant women and 
their unborn babies, potentially because of the stigma around drug use and pregnancy. There is a 
need to intervene to improve birth outcomes and improve postpartum HCV treatment adherence 
in women with SUD. 
The proposed public health intervention will incorporate an educational booklet that is 
based on the Information-Motivation-Behavioral skills (IMB) model. This self-guided booklet 
will be given to women at risk for pregnancy who are currently involved in SUD treatment in the 
Greater Pittsburgh Area, and will contain HCV prevention and treatment information, as well as 
a daily paper diary used in conjunction with their treatment to yield better outcomes because of 
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the behavioral motivation. The ‘Baby and Me, Without Hep C’ booklet program will be a low-
cost way for already established pregnancy/SUD centers to potentially lessen the burden of HVC 
infection on mothers and babies.  
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1.0  INTRODUCTION 
The increase in opiate abuse among all populations has caused great concern for special 
populations, such as pregnant women. One of the implications of pregnant women using opiates 
is the effect that it has on the unborn infant. In addition to putting the baby at risk for neonatal 
abstinence syndrome (NAS), a condition that an opiate addicted infant will experience after 
exposure to drugs in-utero, the baby is also at risk for contracting hepatitis C from an infected 
mother (“U.S. National Library,” 2015). With an estimated 5% risk of vertical transmission, HCV 
infection during pregnancy generates several concerns, including the effect of pregnancy on the 
course of chronic HCV infection, and the impact of maternal infection on pregnancy outcomes 
(Huges, 2017).  
 In the tri-state area of Pennsylvania, Ohio, and West Virginia, the opiate epidemic has hit 
relatively harder than in other areas of the United States. Because of the vast numbers of 
individuals with SUD, area health entities have begun incorporating and innovating SUD treatment 
into everyday practice. In 2014, the city of Pittsburgh opened a state-of-the-art center to treat 
pregnant women with opiate use disorder. The Pregnancy Recovery Center is located at Magee-
Women’s Hospital of UPMC, and offers comprehensive care for women with opiate addition by 
caring for both the developing fetus and the mother (Kreps, 2017). 
 Despite the urgent push for comprehensive care for individuals with SUD, the treatment of 
HCV as it relates to pregnancy and SUD has been neglected (Pergam, 2008). While substance 
 2 
abuse treatment centers tailored for pregnant women provide many services to improve the 
outcomes for both mom and baby, they can benefit by having an additional service that encourages 
HCV infection prevention and treatment initiatives.  
1.1 OPIOID EPIDEMIC AND INJECTION DRUG USE 
In the 1990s, a new approach was adopted in regard to pain management, allowing for more 
chronic pain sufferers to have access to opioid painkillers. Drugs once used only for cancer patients 
going through rigorous treatments were made available to anyone with pain and a prescription for 
opiates. Opioids reduce the intensity of pain signals reaching the brain and affect those brain areas 
controlling emotion (“Misuse of Prescription Drugs,” 2016).  In turn, that lessens the effects of the 
pain. Many opiates affect the brain regions that are involved in reward, resulting in a euphoric 
response. Because of this phenomenon, many who abuse opioids may seek to intensify their 
experience by taking the drug in ways other than prescribed. Inevitably many turn to an even more 
potent and dangerous drug, heroin. 
Both the Centers for Disease Control and Prevention (CDC) and Agency for Healthcare 
Research and Quality (AHRQ) agree that the opioid epidemic has caused over 500,000 preventable 
deaths since 2000 nationwide. Since the year 2002, heroin-related overdose deaths have increased 
286 percent nationwide ("Today's Heroin Epidemic," 2015). 
In 2015, heroin was the most frequently identified drug in autopsies.  Autopsy reports 
indicate that upwards of 55 percent of the 3383 drug related overdose victims had heroin in their 
system (“Today’s Heroin Epidemic,” 2015) Nearly 200 overdose deaths have been reported in 
2016 in Allegheny County, Pennsylvania alone (Bowling, 2014).  The statewide drug overdose 
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death rate in Pennsylvania is nearly twice that of the national overdose death rate (26 per 100,000 
people vs 14.7 per 100,000 people) ("Today's Heroin Epidemic,” 2015).  Unlike other drug-related 
epidemics that North America has faced, the opioid epidemic has hit rural communities the hardest, 
further exacerbating the associated human suffering and productivity loss (Harrison, 2016). 
Although white males between the ages of 30 to 39 years old have the highest number of overdose 
related deaths in Pennsylvania, the rate of fatal overdoses among women is increasing quicker than 
that of the rate of men (Fucco, 2016).  In addition to the immediate effects of opioid use on an 
individual, new data show that the rate of infants born with drug abuse-related problems, such as 
neonatal abstinence syndrome (NAS), has risen 250 percent from 2000 to 2015.  In 2016 alone, 
19.5 out of every 1,000 newborn hospitalizations are the result of the mother’s painkiller or heroin 
use (Observer-Reporter, 2016).    
Those addicted to opioid painkillers are 40 times more likely to become addicted to heroin 
than those not addicted to opioid painkillers. Fortunately, there is well-supported scientific 
evidence that individuals with SUD can be effectively treated with reoccurrence rates similar to 
those of other chronic illnesses like diabetes, asthma, and hypertension (“HHS takes strong steps,” 
2015). One of the more effective treatments for substance use disorder is medication assisted 
treatment (MAT), which typically involves a combination of synthetic opiates such as methadone, 
buprenorphine, or naltrexone with counseling, behavioral therapies, and harm reduction strategies 
(“Today’s Heroin Epidemic”, 2015). Mentioned earlier, the innovative recovery centers for 
pregnant women are utilizing MAT on an outpatient basis. 
There are also several more unconventional approaches to helping those with SUD. 
Although not yet legal in many states, clean needle exchanges have arisen with the intentions of 
providing a safe place for drug users to obtain safe injection materials to lower the risk of 
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contracting needle borne diseases.  Clean needle exchanges have in fact been proven to be an 
effective public health intervention that reduces the transmission of diseases by intravenous drug 
use, as well as not further encouraging the use of illegal drugs (“HHS takes strong steps,” 2015). 
Most needle exchange programs also offer additional services including HIV/AIDS counseling 
and other STD testing, as well as strategies and education materials for preventing sexually 
transmitted infections.  
1.2 SUBSTANCE USE DISORDER IN PREGNANT WOMEN 
A study published in 2007 noted that in the United States, women are at the highest risk for 
developing some form of a substance use disorder during their reproductive years, particularly 
between ages 18-29 (Frances, 2008). Substance use before, during, and after pregnancy poses risks 
to the developing fetus and the newborn infant, as well as the mother. Women with SUD are 
typically at higher risk of sexually transmitted infections, such as HIV and HCV. Additionally, 
women with SUD typically have higher rates of unmet reproductive health needs, comorbid 
psychiatric illness, and postpartum depression (PPD) in comparison to women without SUD (Heil, 
2011). Failure to complete the full course of substance use treatment is associated with poor 
adherence to prenatal care, poor prenatal nutrition, and the worsening or initiation of concomitant 
psychiatric illnesses (Benningfield, 2010). Pregnant women with SUD, as well as their children, 
are more susceptible to psychosocial problems than pregnant women without SUD. Childhood 
sexual abuse, intimate partner violence, posttraumatic stress disorder, and overall psychological 
distress are just a few of the concerns that women with SUD are more likely to have experienced 
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in their lifetime (Engstrom, 2012). All of those concerns can contribute to poor health and a 
compromised well-being in pregnant women with SUD. 
1.3 HEPATITIS C VIRUS IMPLICATIONS  
Currently, approximately 3.7 million people living in North America have hepatitis C. The number 
of HCV-related deaths rose from 333,000 in 1990 to over 704,000 in 2013. This drastic increase 
reflects the high incidence of HCV through the mid-twentieth century, as well as the increase in 
parenteral procedures and injection drug use in the 1940s (Salvi, 2016). The estimated prevalence 
of HCV in pregnant women in the United States is 4% (Huges, 2017) 
 A blood borne disease, hepatitis C is a small, positive-strained RNA-enveloped virus that 
can enter the body through any perforation of the skin. Upon the virus entering the body, it travels 
through the blood and goes to the liver (“Addressing Viral Hepatitis,” 2011). The transmission and 
harboring of HCV are important in individuals with SUD because those individuals are more likely 
to be using unsterile injection materials and have underlying liver issues due to alcohol abuse 
(Takahashi, 2001). Although the primary means of HCV transmission is direct percutaneous 
exposure to infected blood, HCV may also be transmitted sexually. However, sexual transmission 
of HCV is much less likely than sexual transmission of other blood-borne viruses, like hepatitis B 
(HBV) and human immunodeficiency virus (HIV) (Terrault, 2002). Like most all other infections 
that can be transmitted sexually, HCV infection rates are higher in people who have more than one 
partner and highest in those co-infected with HIV (“Addressing Viral Hepatitis,” 2011).  
Most people with a HCV infection are asymptomatic. The virus is not able to be detected 
in the blood for approximately seven to twenty-one days, and only 15 to 25 percent of infected 
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individuals are able to clear the infection. Of those who are unable to fight off the infection, 75-
85% will end up with chronic hepatitis C. Disease progression is slow, presenting anywhere from 
20-30 years after the initial infection, and typically in the form of severe liver damage (“Addressing 
Viral Hepatitis,” 2011). The only way to determine if an individual is infected with hepatitis C is 
by performing a nucleic acid test (NAT) for HCV RNA, which would allow one to see whether or 
not there are anti-HCV antibodies present (Thomas, 2011).  
 Hepatitis C is one of the more genetically diverse hepatitis virus strains, being classified 
into six different genotypic groups. This genetic variation amongst hepatitis virus strains is 
important to understand because certain treatments are significantly more effective on certain 
genotypes than on others (Simmonds, 2001). Although the cost of hepatitis C treatment is high 
regardless of the geographic location and genotype presence, the cost of genotyping for treatment 
alone presents an additional barrier to already disadvantaged areas. The most common genotype 
in North America is genotype 1, accounting for 75% of all infections (Messina, 2015).  
The World Health Organization (WHO) argues that greater access to HCV testing and 
better surveillance are important steps to both increase the number of persons diagnosed with 
HCV, and to improve understanding the distribution of HCV infection in groups of increased risk 
(“Guidelines for the Screening,” 2016). In 2012, the WHO released recommendations for the 
prevention of HCV infection among people who inject drugs, which can be found in Table 1 below 
(“Guidance on prevention,” 2012).  
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Table 1. WHO Recommendations for Prevention of HCV Infection Among People Who 
Inject Drugs 
 
1 Offer people who inject drugs the rapid hepatitis B vaccination regimen. 
2 Offer people who inject drugs incentives to increase uptake and complete the hepatitis B vaccination schedule. 
3 Implement sterile needle and syringe programs that also provide low dead-space syringes for distribution to people who inject drugs. 
4 Offer peer interventions to people who inject drugs to reduce the incidence of viral hepatitis. 
5 Offer opioid substitution therapy to treat opioid dependence, reduce HCV risk behavior and transmission through injection drug use, and increase adherence to HCV treatment. 
 
HCV infection plays a significant role in adverse outcomes in pregnancies, for both 
mothers and babies. Infants born to women infected with HCV were more likely to be small for 
gestational age, have low birthweight, require admission to a neonatal intensive care unit, and 
require assisted ventilation. Maternal HCV infection is significantly associated with fetal growth 
restriction as well as low birthweight (Pergam, 2008). However, it is difficult to know for certain 
whether the increased risk of the above-mentioned fetal outcomes is due to the viral effect of HCV, 
or to the potential cofounders in women with SUD and HCV infection. These potential cofounders 
will be discussed in section 2.2.  
In women who are HIV negative, the risk of vertical transmission, or the chance that the 
virus is passed from mother to child, is 5.8 percent. Maternal HIV coinfection is the most important 
risk determinant of vertical transmission of HCV (adjusted odds ratio, 2.56 [95% CI, 1.50-4.43]), 
with an estimated risk of 10.8 percent (Benova, 2014). Vertical transmission of HCV has been 
found to be a risk only for women with detectable HCV RNA during pregnancy, as opposed to 
detectable HCV antibody, but the level of HCV present in the blood has yet to be determined as a 
risk factor (Benova, 2014).  
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2.0  CURRENT PUBLIC HEALTH INTERVENTIONS 
The need to improve outcomes in people with SUD has become a public health priority. The 
subsequent sections outline SUD and HCV treatment among pregnant women. 
2.1 SUBSTANCE USE DISORDER TREATMENT FOR PREGNANT WOMEN 
A widely accepted therapy for individuals with SUD is MAT. MAT is unique in that it combines 
behavioral therapy with pharmacotherapy, presumably bettering the outcomes for people with 
SUD (Substance Abuse and Mental Health Services Administration, 2011). Most all treatment 
plans emphasize the need for behavioral therapies, as they typically address the underlying causes 
for a person’s substance use. To effectively treat SUD, strategies must be integrated with efforts 
to address substance use disorder and associated infectious diseases, such as HCV. Although MAT 
is considered as an effective, evidence-based treatment, it is important to note that it is not 
successful for all individuals. 
Pittsburgh, Pennsylvania, is home to one of the first centers that focuses on both obstetrics 
and opiate dependence. Located at Magee-Women’s Hospital of UPMC, the Pregnancy Recovery 
Center is a collaboration between four local Managed Care Organizations (MCOs) and the 
Allegheny County Office of Behavioral Health. The Pregnancy Recovery Center utilizes a newer 
pharmacotherapy called buprenorphine to help opiate dependent mothers. Buprenorphine has been 
found to yield overall better birth outcomes and less severe neonatal abstinence syndrome (NAS) 
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compared to the other opiate withdrawal drug, methadone (Jones, 2012). Although still effective, 
the use of methadone during pregnancy poses a risk because it can be abused.  
Located in the Greater Cincinnati area, the Helping Opiate-addicted Pregnant women 
Evolve (HOPE) Program develops personalized care plans to reduce the risk of preterm birth and 
optimize pregnancy outcomes. The HOPE program provides pregnant women with the following: 
• case management,  
• social work support,  
• referrals to available community support services,  
• nutrition counseling,  
• financial counseling,  
• referrals to methadone maintenance treatment facilities/Subutex providers,  
• ongoing follow up with MMT facility counselors,  
• referrals to outpatient and inpatient treatment facilities,  
• referrals to prenatal care,  
• ongoing patient follow up at one of the local prenatal clinics, and 
• prenatal care and follow up care for high risk pregnancy problems. 
The HOPE Program uses outcome measures such as neonatal birth weight, compliance 
with prenatal appointments, and involvement in chemical dependency treatment programs to 
determine the effectiveness of the program (HOPE Program, n.d.). 
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2.2 HEPATITIS C SCREENING AND TREATMENT FOR PREGNANT WOMEN 
Currently, the American College of Obstetricians and Gynecologists (ACOG) and the CDC 
recommend the pregnant women be screened based upon their risk of acquiring HCV. The standard 
screening test for HCV is an anti-HCV antibody test, which indicates whether the individual has 
an active HCV infection, the patient had a past infection that has resolved, or the result is a false 
positive (Trooskin, 2015). However, some researchers have suggested universal prenatal 
screening, regardless of what the woman’s risk for contracting HCV is (Huges, 2017). The 
strengths and limitations of universal screening are outlined later in section 2.3.  The HCV 
screening recommendations of the ACOG and CDC are outlined in Table 2 below.  
 
Table 2. Women in Whom Prenatal Screening for Hepatitis C Virus is Recommended 
1 Women who ever injected illegal drugs (even once). 
2 Users of intranasal illicit drugs. 
3 Women ever on long-term hemodialysis. 
4 
Women with percutaneous/parenteral exposures in unregulated setting (for example, 
tattoos received outside of licensed parlors or medical procedures done in settings 
without strict infection control policies. 
5 Recipients of transfusions or organ transplants before July 1992 and recipients of clotting factor concentrates produced before 1987. 
6 Recipients of blood products from donor who later tested positive for HCV. 
7 Women with History of incarceration. 
8 Women seeking evaluation or care for sexually transmitted infection, including HIV. 
9 Women with unexplained chronic liver disease (including persistently elevated ALT). 
Society for Maternal-Fetal Medicine. HCV in Pregnancy. Am J Obstet Gynecol 2017. 
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Although HCV viremia can be detected in the blood approximately three weeks after 
exposure, the actual diagnosis of HCV depends on the detection of anti-HCV antibodies, which do 
not typically present until two to six months after exposure (Workowski, 2015). 
2.3 INFORMATION-MOTIVATION-BEHAVIORAL SKILLS MODEL OF RISK 
BEHAVIOR CHANGE 
The Information-Motivation-Behavior Skills (IMB) model has been used to design interventions 
that have ultimately improved medication adherence and clinical outcomes in HIV-infected 
persons. A study conducted at the University of Connecticut evaluated the effect of an AIDS risk 
reduction intervention on AIDS risk behavior in a college student population by using the IMB 
model to design, implement, and evaluate the intervention (Fisher, 1996).   
The intervention consisted of three sessions, all conducted by health educators. In the first 
session, information about AIDS risk behavior that targeted information gaps was presented. In 
the second session, the motivation component, small group discussions were guided by peer 
educators, and then large group discussions guided by health educators followed by a screening of 
a movie (Fisher, 1996). The first two sessions aimed to change attitudes and norms regarding 
preventive behavior, as well as influence perceptions of support networks, and expectations for 
safer sexual behavior. The final session, comprised of the behavioral skills, taught students how to 
initiate and maintain safer sexual behavior, and on perceptions of self-efficacy and response 
efficacy.  
To evaluate the effectiveness of the intervention, pre- and postmeasures consisted of self-
administered scales designed to assess AIDS risk reduction information, motivation, behavioral 
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skills, and AIDS risk and AIDS preventive behavior (Fisher, 1996). One month after the 
intervention, the following were found to be increased at both the individual and group levels: 
AIDS risk reduction information, improved attitudes toward the performance of AIDS preventive 
acts, behavioral interventions to adopt preventive behaviors, perceptions of effectiveness of AIDS 
preventive behaviors being enacted, condom accessibility, safer sex negotiations, and condom use 
during sexual intercourse (Fisher, 1996). The use of an IMB model intervention also had a 
significant effect on follow-up HIV testing. In using the IMB model, one can identify modifiable 
and measurable determinants of behavior, providing an opportunity to improve the mechanisms 
that underlie decision making at both the individual and group levels (Campbell, 2000).  The 
presence of both information and motivation is thought to lead to behavior skills being acquired, 
ultimately leading to behavior change. Because of its success in AIDS risk reduction, the IMB 
model can be used as a guide for the design, implementation, and evaluation of risk reduction 
interventions targeted at the needs of specific populations (Fisher, 1996).  
2.4 DISCUSSION 
In general, the effective coordination of care is an essential part in the quality of healthcare. 
Although there are organizations that emphasize such coordination and the use of evidence-based 
care, some SUD treatments have limited resources, ultimately preventing this coordination. From 
a historical standpoint, SUD treatment is provided on an ‘as needed’ basis, meaning that a person 
usually does not pursue treatment until they experience a negative episode relating to their drug 
use (Institute of Medicine, 2006). Additionally, there are no concrete or universal measures of 
 13 
success when it comes to SUD treatment, making outcome metrics difficult to capture across all 
of the different treatment facilities.  
The ongoing debate as to whether or not all pregnant women should be screened for HCV 
poses a significant public health consideration as it weighs the potential cost of the screens with 
the logistics of linking women to the indicated care. In identifying HCV infection early in 
pregnancy, or even before pregnancy, measures can be taken to properly manage and monitor the 
status of the liver, while also preparing to care for an infected neonate (Ly, 2017).  
Until 2011, the standard pharmacotherapy for HCV infection was a combination of pegy-
lated interferon (PEG-IFN) and Ribavirin. However, both of these drugs have side effects and 
contraindications that advise against use in pregnant women. Ribavirin is an FDA classified 
Category X drug because of embryocidal and teratogenic effects observed in animals. Because of 
this, Ribavirin is not recommended for women of child bearing age (“EASL Clinical Practice,” 
2011). Since the discovery of the adverse effects of Ribavirin in pregnancy, new pharmaceuticals 
have been developed and approved for HCV treatment, but there are still no studies available that 
show the effects on pregnant women. Of the newer medications known as direct-acting antivirals 
(DAA), the medication with the best outcomes in animal studies is Sofosbuvir. Sofosbuvir works 
by fully inhibiting one of the HCV polymerase active sites, thus blocking viral RNA synthesis 
(“Sofosbuvir summary,” n.d.). Sofosbuvir has the potential to become the standard-of-care for 
women of childbearing age with HCV because of its safety and effectiveness in animal trials.  
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3.0  PROPOSED INTERVENTION 
Based upon current research, there are mutual understandings and agreements in the medical and 
scientific communities that HCV prevention, treatment, and management in pregnant women with 
SUD is lacking. With that, proposed is an education campaign for pregnant women with SUD that 
utilizes the IMB model in the form of self-report journals to provide women with the education 
and motivation to change their behavior. The goal of the education campaign is to change women’s 
behaviors to prevent HCV infection, improve birth outcomes, and better the outcome of HCV 
treatment postpartum.  
3.1 STUDY POPULATION 
The target population for the education campaign is women of childbearing age seeking treatment 
for SUD. Because this campaign is aimed at the prevention and treatment of HCV, both women 
with and without HCV will be engaged. As mentioned above, women of childbearing age, 
particularly between the ages of 19-29, are at the highest risk of getting an HCV infection. Because 
this education campaign is aimed at improving the outcomes of HCV infection, there will not be 
many exclusionary criteria. Women entering residential alternatives to incarceration are also 
eligible to participate, with the permission of their treatment case worker. During the 18-month 
pilot, 200 women total are to be engaged by receiving self-report journals.  
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3.2 STUDY SETTING 
The Greater Pittsburgh area has several state-of-the-art services for individuals with SUD. Given 
the treatment clinics, mental health support, and inpatient facilities, there are many opportunities 
to integrate a unique addition in the Greater Pittsburgh area. This pilot study will not be housed in 
one particular location, rather it will be a collaboration among different providers with the 
oversight of a project coordinator. Because there is no central location, and the “Baby and Me” 
journals will be completed by the participants on their own time, it is up to the project coordinator 
and care specialists (role to be explained further in section 3.4) to keep track of adherence to 
completing the journals.  
As mentioned, Magee-Women’s Hospital of UPMC’s Pregnancy Recovery Center was 
created in conjunction with four area managed care organizations (MCOs), including Community 
Care Behavioral Health Organization, UPMC for You, Gateway Health, and United Healthcare 
for Families and Communities, providing pregnant women with SUD the opportunity to begin 
treatment with buprenorphine on an out-patient basis, all while integrating it into their obstetric 
care (Kreps, 2014). Women in the Pregnancy Recovery Center will fit the inclusion criteria 
because of their concomitant SUD diagnosis and pregnancy. Collaborating with the Pregnancy 
Recovery Center can help mothers remain HCV free through the pregnancy, or better the birth 
outcomes of an HCV positive woman.  
Women will also be recruited from the numerous SUD centers in the Greater Pittsburgh 
Area, including but not limited to, Confidential Outpatient Addiction Treatment Center of 
Pittsburgh, Recovery Pathways, Trinity Wellness Services, South Hills Recovery Project, Journey 
Healthcare, Community Psychiatric Centers Professional Mental Health Services, Right Track 
Addiction Services, and New Life Renewal Services. Physicians who prescribe buprenorphine 
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independently can also recommend this to their eligible female patients to participate in this 
educational campaign.  
In addition to recruiting from SUD treatment centers and buprenorphine prescribers, a mass 
email will be sent to all obstetric and gynecological providers within the greater Pittsburgh Area. 
To prevent health coverage limitations, this pilot study does not have any direct affiliation with a 
medical system. 
3.3 STUDY AIMS AND GOALS 
The ultimate aims of the pilot study are to change women’s behaviors to prevent HCV infection, 
to improve birth outcomes, and to better the outcome of HCV treatment postpartum.   
The goals of the educational campaign are the following: 
• Women of child bearing age seeking SUD treatment have increased knowledge of 
HCV transmission risks; 
• Women of child bearing age seeking SUD treatment have increased understanding 
of recommendations to improve birth outcomes in HCV positive women; 
• Women of child bearing age seeking SUD treatment are willing to seek HCV 
treatment postpartum (if indicated); 
• Women with SUD are empowered to work with their health care providers to 
establish a plan of care to achieve the best possible outcomes for themselves and 
their neonates; 
• Women with SUD will decrease engagement in riskier behaviors that may result in 
HCV infection; 
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• Pregnant women with SUD in the greater Pittsburgh area have improved health 
outcomes; 
• Pregnant women with SUD in the greater Pittsburgh area have improved HCV 
outcomes;  
• Neonates born to women with SUD in the greater Pittsburgh area have improved 
health outcomes; and 
• Neonates born to HCV positive women in the greater Pittsburgh area have 
improved health outcomes.  
3.4 PILOT STUDY 
In the pilot of the educational campaign, mixed methods will be used to engage with at least 200 
women of childbearing age who are diagnosed with SUD and at risk of HCV in the greater 
Pittsburgh area. Behavioral responses will be collected by means of self-report data. Quantitative 
birth outcomes will also be measured. Further outlined later in this section, an educational self-
report journal will be completed by the target population in efforts to capture behaviors that can 
influence SUD and HCV infection outcomes. By utilizing a mixed methods approach influenced 
by the Information-Motivation-Behavioral Skills model, it is expected to yield positive outcomes 
in regards to HCV education and prevention because the participants may answer more honestly.  
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3.4.1 TRAINING AND RECRUITMENT 
The first step of the “Baby and Me, Without Hep C” campaign is getting IRB approval. Because 
personal patient health information will be shared, it is assumed that the IRB needs to approve of 
the self-report journals and recruitment materials. During this approval period, overall recruitment 
for providers will also begin. This will include hiring program personnel. The program personnel 
will be responsible for establishing relationships with the community providers (such as the MAT 
clinics, probation officers, and obstetric providers), and training those personnel on how to 
distribute the self-report journals to eligible women.  
For providers, participation in the pilot campaign requires minimal effort. Providers will 
be enticed to participate because all of the education materials distributed are from pre-existing 
documents and recommendations. All of the documents utilized are open access, and any 
references with copyrights will be appropriately acknowledged. By doing this, not ‘reinventing the 
wheel,’ providers should be at ease that these are already valid materials and that they do not have 
to invest in anything other than time to pass the documents out to participants. Essentially, all the 
community partners/stakeholders will be responsible for is passing out flyers and self-report 
journals to eligible women. Questions and concerns from the participating sites will always be 
welcomed by the care coordinators, program coordinators, and program director. The purpose of 
the ease of use is to be able to build upon the program after establishing relationships. 
3.4.2 PARTICIPANT RECRUITMENT AND MATERIALS 
Upon developing relationships with the participating providers, the second step of the education 
campaign will be to identify and recruit eligible women for the campaign. Over a 12-month 
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recruitment period, self-report journals will be distributed to 200 women seeking SUD treatment 
within the Greater Pittsburgh Area. Over the 12-month recruitment and data collection period, the 
program personnel will be in contact with the distribution sites, as well as the patients, to answer 
any questions that may present.  
As for recruitment, all eligible women will be handed a flyer about participating in the 
campaign. Putting the information on a flyer allows the woman to be in charge of taking the 
initiative to pursue participation, rather than being influenced by the provider. If a woman indicates 
that she would like to participate, the provider will distribute the self-report journal, and notify the 
program coordinator of the potential participant’s locator information within 24 hours. Within 
three business days of the woman expressing interest, program personnel will contact her via her 
preferred method to further explain the purpose of the ‘Baby and Me, Without Hep C’ campaign, 
as well as address any questions she may have. The woman will be informed that she can contact 
the program personnel at any point during her participation if she were to have any questions.  
The self-report journals will act as an educational booklet, as well as a diary for women to 
feel more empowered and motivated during their SUD treatment to stay HCV free, or to empower 
them to pursue HCV treatment postpartum if indicated. The journals will be distributed in print, 
but can also be accessed and completed electronically as a PDF. The journals will be composed of 
the following sections: 
1. Hepatitis C Education- The purpose of the HCV education section is 
to empower to woman to pursue HCV screening throughout her 
pregnancy. The HCV education section will consist of patient focused 
education materials directly from the CDC and NIH National Institute 
of Diabetes and Digestive and Kidney Diseases. The information will 
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be thorough enough for women to understand the severity of hepatitis 
C, while easy enough to understand so that the woman is not 
overwhelmed. At the end of the Education Section, a competency 
survey can be found. This competency survey should be completed by 
the participating woman. 
2. Prenatal Preparation- This section of the booklet will explain the risks 
that HCV poses for pregnancy, both for mother and baby. This section 
will reiterate the importance of safe injection practices and further 
encourage SUD treatment. Communication with the woman’s 
obstetrician will also be emphasized in this section. 
3. Postpartum Care- this section will provide resources for women to 
pursue HCV treatment postpartum, if indicated. A list of providers who 
treat HCV will be found here, and can be personalized by the 
participant, or medical provider, with appointment and follow-up 
information. 1 
4. Diary- This section of the booklet will be used to capture the woman’s 
entire experience, including SUD treatment, prenatal care, antenatal 
care, postpartum care, and HCV education segment. The diary portion 
will encourage the mother to change her behaviors through the course 
                                                 
1 Upon the design of this campaign, extensive information about the treatment and management of HCV was 
going to be included in this section. However, after beginning to develop the program and complete further 
research, it was determined that the journal would best serve as a tool to motivate women at risk for pregnancy 
and HCV to prevent infection and pursue treatment, if need be. By doing this, the woman will not be 
overwhelmed with too much information that she may not be able to fully understand. 
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of her SUD treatment to not only better the outcomes of her treatment, 
but also to better the outcomes of her pregnancy when the time comes.  
5. Emergency contact information- Because many women experiencing 
SUD also have disadvantaged living situations, a list of providers, from 
food services to crisis relief centers, will be provided at the end of the 
booklet. 
6. Neonate outcomes- This section will not be filled out by all 
participants. Because the inclusion criteria being women of child 
bearing age, and not necessarily just pregnant women, there will also be 
women who never are pregnant during this pilot recruitment.  
7. Evaluation surveys- At the end of booklet, participants will be asked 
questions relating to whether or not they learned anything during the 
education campaign. The responses for the questions will be on a Likert 
scale. 
 
3.4.3 DATA COLLECTION 
Data collection and evaluation will occur on a rolling basis and will end exactly 12 months after 
the 200th individual engages by receiving access to a journal. One-hundred twenty women are 
expected to complete the journals in their entirety and submit them. Upon the completion of each 
individual self-report journal, the woman is to contact the associated program personnel to arrange 
pick-up. If the woman is pregnant, she will also have the option to report birth outcomes in the 
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‘Neonate Outcomes’ section of the journal. The purpose of capturing the birth outcomes is to 
eventually compare them with an adjusted control that did not receive educational intervention.  
During provider recruitment, providers and office staff will be given the opportunity to 
submit observation forms that capture the following metrics: overall ease of program integration 
into office flow, and overall impact of program among patients. Similarly, as a part of the self-
report journals that the participants receive, the female participants will also have the opportunity 
to submit experience forms that capture the following metrics: ease of joining program, overall 
impact of program on SUD diagnosis, overall impact of program on HCV diagnosis, increase in 
SUD knowledge, increase in HCV knowledge. Table 3 below outlines the observation forms, from 
both providers and participants, that may be submitted at any time to showcase the impact of the 
program. The purpose of allowing the participating women to speak with program personnel is to 
empower them to pursue further care of HCV (if indicated), and to continue preventing HCV 
infection. By using ordinal scales to determine the degree to which the providers and participants 
feel a certain way, the program personnel will be able to immediately see whether or not the 
program is being received well at any given location.  
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Table 3. Observation Forms for Providers and Participants 
Provider Observation Form 
“Baby and Me: Without Hep C” 
 1: Strongly 
Agree 
2: Agree 3: Neutral 4: Disagree 5: Strongly 
Disagree 
N/A 
I feel that the 
program is easy to 
integrate into our 
office flow… 
      
Comments:  
I feel that the 
program has a 
positive impact on 
the participating 
patients… 
      
Comments:  
 
Participant Observation Form 
“Baby and Me: Without Hep C” 
 1: Strongly 
Agree 
2: Agree 3: Neutral 4: Disagree 5: Strongly 
Disagree 
N/A 
I feel that the 
program was easy to 
join… 
      
Comments:  
I believe that 
participating in this 
program has 
positively affected 
my SUD diagnosis… 
      
Comments:  
I believe that 
participating in this 
program has 
positively affected 
my HCV diagnosis… 
      
Comments:  
This program has 
increased my 
knowledge on 
SUD… 
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Table 3 Continued 
Comments:  
This program has 
increased my 
knowledge on 
HCV… 
      
Comments:  
The timeline for the ‘Baby and Me, Without Hep C’ campaign is illustrated in the appendix. 
3.5 DATA ANALYSIS 
Data analysis will be conducted on a rolling basis, with an inductive approach. First, all open-
ended entries in the journal will be transcribed, coded, and sorted into related categories. The 
categories will be examined, and if relationships presented, they will be noted and evaluated. The 
purpose of this program is not to prove that the IMB model provides improved health outcomes, 
but rather, the information gathered will be used to determine whether or not the IMB model can 
be used to improve health outcomes.  MAXQDA, a software program designed to facilitate and 
support qualitative, quantitative, and mixed methods research projects, will be used to cross-
examine relationships and to determine if there are any significant findings. MAXQDA was 
chosen as the data analysis database because it focuses on mixed methods research, linking 
qualitative text analysis and quantitative methods (“MAXQDA:…,” n.d.). Trained project 
personnel will run the data analysis to determine if there are any recurrent themes in the narratives.  
Although women with SUD may share some fundamental aspects of their experience with 
SUD, it is expected that the open-ended portions will still be vastly different. All of the open-ended 
portions of the diary will be examined to determine if there is any type of trends in reporting (i.e., 
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reporting disadvantaged living situations, abusing painkillers, etc.). The decision to use qualitative 
data was made to fully capture exactly what the woman wants to say, and to see exactly how their 
life factors are influencing their health. The qualitative, open-ended portions of the journal are 
being utilized in place of in-person interviews to save on time of the providers. The use of self-
reported journals are being used under the premise that women are going to feel more empowered 
to complete them, and complete them honestly. The women who will be participating are already 
pursuing SUD treatment, so that alone suggests that they may be more willing to further engage in 
a program as such.   
The entire journal will have Likert based responses to determine competencies influenced 
by the IMB model, and to determine whether or not the program goals were met. The competency 
surveys will then be compared to the evaluation surveys at the end of the journals. How 
measurements are to be assessed are outlined in Table 4 below. 
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Table 4. Assessment of Measurements 
Measures of Information 
Goals Location in program Data type 
Women of child bearing age seeking SUD treatment 
have increased knowledge of HCV transmission 
risks.  
• Competency survey 
in Hepatitis C 
Education section. 
• Ordinal 
• Open-ended 
Women of child bearing age seeking SUD treatment 
have increased understanding of recommendations 
to improve birth outcomes in HCV positive women.  
• Competency survey 
in Prenatal 
Preparation section. 
• Ordinal 
• Open-ended 
Measures of Motivation 
Women of child bearing age seeking SUD treatment 
are willing to seek HCV treatment postpartum (if 
indicated). 
• Competency survey 
in Postpartum Care 
section.  
• Ordinal 
• Open-ended 
Women with SUD are empowered to work with their 
health care providers to establish a plan of care to 
achieve the best possible outcomes for themselves 
and their neonates. 
• Competency survey 
in Hepatitis C 
Education section. 
• Ordinal 
• Open-ended 
Measures of Behavior 
Women with SUD will decrease engagement in 
riskier behaviors that may result in HCV infection.  
• Competency survey 
in Hepatitis C 
Education section. 
• Ordinal 
• Open-ended 
Pregnant women with SUD in the greater Pittsburgh 
area have improved health outcomes. 
• Competency survey 
in Neonate 
Outcomes section. 
• Ordinal 
• Open-ended 
Pregnant women with SUD in the greater Pittsburgh 
area have improved HCV outcomes. 
• Competency survey 
in Neonate 
Outcomes section. 
• OB/GYN reporting 
• Ordinal 
• Open-ended 
Neonates born to women with SUD in the greater 
Pittsburgh area have improved health outcomes. 
• Competency survey 
in Neonate 
Outcomes section. 
• OB/GYN reporting 
• Ordinal 
• Open-ended 
Neonates born to HCV positive women in the greater 
Pittsburgh area have improved health outcomes. 
• Competency survey 
in Neonate 
Outcomes section. 
• OB/GYN reporting 
• Ordinal 
• Open-ended 
 
 The information captured in the education campaign journals will inform women, motivate 
them, and have them make better behavioral choices to improve SUD and HCV outcomes.  
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4.0  STRENGTHS AND LIMITATIONS 
There are several strengths to this proposed educational campaign. First and foremost, 
participation requires minimal effort by providers, enticing them to engage with eligible women 
and distribute self-report journals to them. Second, by utilizing self-report journals, women may 
feel more in charge of their care, and therefore may answer more honestly. However, considering 
the diaries are self-report, they also may be wary of judgment or discrimination, and may not 
answer truthfully. Because the education campaign is targeting women of child bearing age, 
women may feel that they could be treated negatively (if pregnancy results) while pursuing SUD 
treatment.  
One limitation that is discussed in the assumptions portion of the logic model is that there 
may not be sufficient interest amongst eligible women or amongst treatment providers. To address 
this, care coordination specialists can encourage potential providers by ensuring that there is 
minimal effort required on their part. As for gaining interests of the target population, one way to 
encourage participation is to reiterate that they are already involved with a treatment structure and 
that their participation in the education campaign yields virtually no risks to them.  
Although SUD and HCV infection is a structural problem, an individual-level intervention 
was implemented for the Baby and Me: Without Hep C program with the hopes that each woman 
would feel empowered to take charge of her care. By directly educating each individual, it is hoped 
to yield better outcomes. With that, the individual-level approach could also act as a major 
limitation by not motivating the participants enough, like a group-level intervention might have. 
The Baby and Me: Without Hep C program is designed to require little funding and time 
commitment from all parties involved. With that, it is thought that the program will be sustainable 
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because of its ‘hands off’ design. However, this could also allow for program aspects to be 
neglected and not be utilized to its full potential, no longer being sustainable. 
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5.0  CONCLUSION 
Despite the urgent push for comprehensive care for individuals with SUD, the treatment of HCV 
as it relates to pregnancy and SUD has notably been neglected. The intended goal of the ‘Baby 
and Me, Without Hep C’ campaign is to better the outcomes for both mothers and babies, and by 
targeting women of child bearing age with SUD. Self-efficacy plays a large factor into health 
outcomes, so in order to produce the best possible outcomes for mother and baby in the case of 
HCV infection, the participating women will be educated and motivated to pursue treatment and/or 
prevention, before, during, and after pregnancy. By integrating this campaign with a woman’s 
SUD treatment, it is showing that her whole well-being is being cared for.  
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APPENDIX: SUPPLEMENTAL TABLE 
Table 5. Timeline 
Activity Involvement Time 
 A. Training and Recruitment 
 Hire Key Personnel Program director, program 
coordinator, care coordinator 
specialists, data analysts 
Month 0 - Month6 
 Self-Report Journal Compilation 
(print and electronic) 
Program director, program 
coordinator 
Month 0 - Month 6 
 IRB Approval Program director, program 
coordinator, IRB 
Month 0 - Month 6 
PILOT STUDY BEGINS 
 Recruit Providers Program director, program 
coordinator, care coordinator 
specialists, providers 
Month 6 – 
Completion 
 Distribute Recruiting Materials 
to Providers 
Program director, program 
coordinator, care coordinator 
specialists, providers 
Month 6 - 
Completion 
 B. Participant Recruitment 
 Distribute Recruiting Flyers to 
Participants 
Program director, program 
coordinator, care coordinator 
specialists, providers, women of 
child bearing age with SUD 
Ongoing 
 Distribute Self-Report Journals 
to Participants 
Providers, care coordinator 
specialists 
12 month duration 
 C. Data Collection and Analysis 
 Collect Data Care coordinator specialists, 
providers 
Ongoing basis from 
start of journal 
distribution 
 Analyze Data Care coordinator specialists, data 
analysts  
Ongoing basis from 
return of journals 
 D. Results 
 Disseminate Findings Program director, program 
coordinator, care coordinator 
specialists, providers, women of 
child bearing age with SUD, 
stakeholders 
Upon completion of 
final engaged 
participant 
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